Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Vivus Pharmaceuticals
>
New low for pharma industry
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 5392915"]I wonder how those reps who they reposted their positions feel about this article?</p><p>One of the pureyors of the newest weight-loss drugs is going on a diet.</p><p><br /></p><p>Vivus , which sells the Qsymia pill, plans to trim its U.S. sales force by about one-third to approximately 100 sales reps, down from 150. At the same time, the drug maker plans to shift some of its spending to “high-value, consumer-focused digital media projects” to support obesity education, according to a statement.</p><p><br /></p><p>The move comes as the drug maker struggles to make its prescription drug stand out among a trio of recent entrants. Over the past 20 weeks, the number of new U.S. prescriptions written for the Vivus pill has remained flat, according to RBC Capital Markets analyst Simos Simeonidis, who cited data from IMS Health and Symphony Health, two different market research firms.</p><p><br /></p><p>Moreover, Qsymia market share also trails those two rival drugs – Contrave, which is sold by Orexigen Therapeutics and Takeda Pharmaceuticals , and Belviq, which is marketed by Arena Pharmaceuticals and Eisai. Using data from Symphony Health, for instance, the Vivus pill has captured 24% of the U.S. market, while the Orexigen drug has 32% and the Arena pill has nearly 44%.[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 5392915"]I wonder how those reps who they reposted their positions feel about this article? One of the pureyors of the newest weight-loss drugs is going on a diet. Vivus , which sells the Qsymia pill, plans to trim its U.S. sales force by about one-third to approximately 100 sales reps, down from 150. At the same time, the drug maker plans to shift some of its spending to “high-value, consumer-focused digital media projects” to support obesity education, according to a statement. The move comes as the drug maker struggles to make its prescription drug stand out among a trio of recent entrants. Over the past 20 weeks, the number of new U.S. prescriptions written for the Vivus pill has remained flat, according to RBC Capital Markets analyst Simos Simeonidis, who cited data from IMS Health and Symphony Health, two different market research firms. Moreover, Qsymia market share also trails those two rival drugs – Contrave, which is sold by Orexigen Therapeutics and Takeda Pharmaceuticals , and Belviq, which is marketed by Arena Pharmaceuticals and Eisai. Using data from Symphony Health, for instance, the Vivus pill has captured 24% of the U.S. market, while the Orexigen drug has 32% and the Arena pill has nearly 44%.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Vivus Pharmaceuticals
>
New low for pharma industry
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Vivus Pharmaceuticals
>
New low for pharma industry
>